Keryx Biopharma Cash Flow - Quarterly (NASDAQ:KERX)

Add to My Stocks
$4.84 $0.02 (0.41%) KERX stock closing price Apr 19, 2018 (Closing)

The Keryx Biopharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Keryx Biopharma profits, the balance sheet shows Keryx Biopharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Keryx Biopharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Keryx Biopharma had cash and cash equivalents of $111.81M at the beginning of the quarter and $93.52M at quarter end for 2017 Q4. KERX decrease in investments stood at a value of $-1.25M for the latest quarter 2017 Q4.

View and download details of Keryx Biopharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Net Income Cash Flow
-163.44M-133.01M-109.51M-23.01M-161.09M-127.31M-85.61M-40.96M-123.14M-85.36M
Depreciation Depletion Amortization Cash-Flow63.65M63.47M63.3M-34.98M34.81M34.62M15.94M11.79M-
Net Increase (Decrease) in Assets Liabilities-14.99M-15.98M-5.43M-7.02M-7.94M-6.14M-6.58M-8.03M-35.57M-30.85M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net21.28M12.21M7.48M3.9M47.44M32.38M14.97M5.32M19.47M13.01M
Net Cash from (used by) Operating Activities
-93.48M-73.31M-44.15M-25.96M-86.6M-66.25M-42.59M-27.72M-127.45M-102.86M
Increase (Decrease) in Prop Plant And Equipment-1.25M-1.17M-0.42M--2.07M-2.06M-2.04M-2.03M-2.77M-0.43M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments--------11.5M11.5M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
-1.25M-1.17M-0.42M--2.07M-2.06M-2.04M-2.03M8.73M11.07M
Issuance (Purchase) of Equity Shares76.56M76.78M73.38M5.09M----119.73M127.93M
Issuance (Repayment) of Debt Securities--------125M-
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-0.1M-0.1M-0.08M-0.02M------8.21M
Net Cash from (used by) Financing Activities
76.46M76.67M73.29M5.06M----244.73M119.71M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
-18.28M2.18M28.71M-20.9M-88.48M-68.11M-44.49M-29.75M126M27.92M
Cash & Equivalents at Beginning of Year111.81M200.29M74.28M55.69M14.67M35.25M28.41M16.38M13.14M19.06M
Cash & Equivalents at Year End93.52M113.99M140.52M90.9M111.81M132.17M155.79M170.53M200.29M102.2M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Keryx Biopharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Keryx Biopharma stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Keryx Biopharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Keryx Biopharma stock price movement.
  • Cash Flow from operating activities: Keryx Biopharma reported a negative operating cash flow of $-93.48M till 2017 Q4 and has seen a decrease from the previous quarter. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-1.25M for KERX stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Keryx Biopharma earned $76.46M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Keryx Biopharma Cash Flow

Quarterly Cash Flow Statements For Keryx Biopharmaceuticals Peers

Dicerna Pharma cash flow, JAPAN TOB INC cash flow, NephroGenex cash flow, Theratechnologies cash flow